Patents by Inventor Bradley Dain

Bradley Dain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080166723
    Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Application
    Filed: July 26, 2007
    Publication date: July 10, 2008
    Applicant: PGxHealth, LLC
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
  • Publication number: 20080020383
    Abstract: The present invention relates to methods for diagnosing or predicting responsiveness to treatment, such as Alefacept, by determining the presence of a nucleotide at one or more polymorphic sites within a haplotype marker. The present invention identifies multiple haplotypes that are associated with response to Alefacept. The haplotype markers identified by the present invention and methods of the invention can be particularly useful for diagnosing or predicting susceptibility to skin diseases, such as Psoriasis.
    Type: Application
    Filed: May 4, 2005
    Publication date: January 24, 2008
    Applicant: GENAISSANCE PHARMACEUTICALS, Inc.
    Inventors: Beena Koshy, Bradley Dain, Madan Anant, Ping Zhan
  • Patent number: 7250258
    Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: July 31, 2007
    Assignee: PGxHealth LLC
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
  • Publication number: 20060166219
    Abstract: Haplotypes in the NTRK1 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these NTRK1 haplotypes are disclosed.
    Type: Application
    Filed: November 22, 2004
    Publication date: July 27, 2006
    Applicant: Genaissance Pharmaceuticals
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20060154265
    Abstract: Haplotypes in the LDLR gene associated: with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these LDLR haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these LDLR haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
    Type: Application
    Filed: January 14, 2005
    Publication date: July 13, 2006
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050277129
    Abstract: Haplotypes in the APOE gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these APOE haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these APOE haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
    Type: Application
    Filed: January 14, 2005
    Publication date: December 15, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050260613
    Abstract: Haplotypes in the LRPAP1 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these LRPAP1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these LRPAP1 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Application
    Filed: October 26, 2004
    Publication date: November 24, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050255488
    Abstract: Haplotypes in the NTRK1 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these NTRK1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these NTRK1 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
    Type: Application
    Filed: October 13, 2004
    Publication date: November 17, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050255495
    Abstract: Haplotypes in the SLC5A7 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these SLC5A7 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these SLC5A7 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
    Type: Application
    Filed: December 7, 2004
    Publication date: November 17, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050255498
    Abstract: Haplotypes in the APOC1 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these APOC1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these APOC1 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
    Type: Application
    Filed: January 14, 2005
    Publication date: November 17, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050255492
    Abstract: Haplotypes in the CHRNA9 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these CHRNA9 haplotypes are disclosed.
    Type: Application
    Filed: November 22, 2004
    Publication date: November 17, 2005
    Applicant: Genaissance Pharmaceuticals
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050255494
    Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Application
    Filed: December 7, 2004
    Publication date: November 17, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050250122
    Abstract: Haplotypes in the APOA4 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these APOA4 haplotypes are disclosed.
    Type: Application
    Filed: November 22, 2004
    Publication date: November 10, 2005
    Applicant: Genaissance Pharmaceuticals
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050250118
    Abstract: Haplotypes in the EPHX2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these EPHX2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these EPHX2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Application
    Filed: October 26, 2004
    Publication date: November 10, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050250121
    Abstract: Haplotypes in the NTRK2 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these NTRK2 haplotypes are disclosed.
    Type: Application
    Filed: November 22, 2004
    Publication date: November 10, 2005
    Applicant: Genaissance Pharmaceuticals
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed
  • Publication number: 20050048543
    Abstract: Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
    Type: Application
    Filed: July 9, 2004
    Publication date: March 3, 2005
    Inventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Denton, Richard Judson, Vural Ozdemir, Carol Reed